Login | Register
Profile | Log out
logo

  • Home
  • News
  • Opinion
  • Other
    • Market Updates
    • Explainers
    • Satire
  • About
  • Contact Us
    • Contact
    • Get Covered
    • Posting Guidelines
  • Subscribe
Submit An Article

biotech

  • Home
  •  
  • biotech



  • Most Read
  • Latest Comments
  • Alcidion secures major UK hospital network for Patientrack health monitoring
    • News

    RBA and ASIC up the ante on blockchain project, ASX writes off millions
    Public
  • Alcidion secures major UK hospital network for Patientrack health monitoring
    • Satire

    Australia to close borders to Omicron Persei 8
    Public
  • Alcidion secures major UK hospital network for Patientrack health monitoring
    • Opinion

    The New Criterion: will the listed sanitiser stocks clean up – or clean out – investors?
    Public
  • Alcidion secures major UK hospital network for Patientrack health monitoring
    • Opinion

    Is this the most hated company on the ASX?
    Public
  • Alcidion secures major UK hospital network for Patientrack health monitoring
    Opening a new frontier in treating Parkinson’s disease
    • Review
    • November 11, 2022
  • Tremors from the FTX collapse continue to be felt as DigitalX sells off 15% Bitcoin holdings
    • Review
    • January 10, 2023
  • AUDC stablecoin gathers momentum as Novatti confirms integration with XRP Ledger
    • Review
    • June 9, 2022
  • PharmAust completes dosing first cohort for MND treatment, patients respond positively
    • Review
    • January 6, 2023
  • Is this the most hated company on the ASX?
    • Review
    • August 16, 2019

Latest Articles

  • Imagion Biosystems Advances MagSense® Phase 2 Trial
    Imagion Biosystems Advances MagSense® Phase 2 Trial
    • News

  • Acrux-developed Menopause Hormone Therapy to enter Australian market
    Acrux-developed Menopause Hormone Therapy to enter Australian market
    • News

  • Emyria Expands Into Victoria as Medibank Backs Mental Health Programs
    Emyria Expands Into Victoria as Medibank Backs Mental Health Programs
    • News

  • PainChek locks in performance data for FDA submission, aiming to be  first pain assessment app approved in US
    PainChek locks in performance data for FDA submission, aiming to be first pain assessment app approved in US
    • News

  • HeraMED eyes TGA reclassification to restore HeraBEAT device for at-home use
    HeraMED eyes TGA reclassification to restore HeraBEAT device for at-home use
    • News

  • Alcidion secures major UK hospital network for Patientrack health monitoring
    • News

    Alcidion secures major UK hospital network for Patientrack health monitoring

    Smart healthcare continues to make strides in the United Kingdom with healthtech company Alcidion (ASX: ALC) to deploy their Patientrack monitoring system across the NHS Lanarkshire, the third largest health board in Scotland.  With approximately 12,000 staff working across communities, health centres, clinics and three district hospitals, the 5-year agreement will see Alcidion roll out

    Read More
    Public
  • Mayne Pharma strengthens oral contraceptives portfolio in lucrative U.S market
    • News

    Mayne Pharma strengthens oral contraceptives portfolio in lucrative U.S market

    With the increasing competition amongst pharmaceutical companies being driven by a proliferation of generic brands, Mayne Pharma Group (ASX: MYX) has secured its position in the U.S as a leading oral contraceptives supplier by partnering with Novast Laboratories for 13 generic products.  Of the 13 products, four have been approved by the U.S Food and

    Read More
    Public
  • Alterity confirms FDA development pathway for Multiple System Atrophy treatment
    • News

    Alterity confirms FDA development pathway for Multiple System Atrophy treatment

    After meeting with the FDA, biopharmaceuticals company Alterity Therapeutics (ASX: ATH) has confirmed Phase II clinical trial plans for their ATH434 compound in the treatment of Multiple System Atrophy (MSA), an incurable Parkinsonian disorder with no regulatory precedent. Due to the unique scenario where there are no accepted efficacy endpoints, guidance has been provided by

    Read More
    Public
  • Eco-toxicity findings confirm Bio-Gene pesticide safe for aquatic life
    • News

    Eco-toxicity findings confirm Bio-Gene pesticide safe for aquatic life

    Following preliminary eco-toxicity studies on limited aquatic species, agtech developer Bio-Gene Technology (ASX: BGT) has reported favourable results for its flagship next-gen insecticide, Flavocide.  The studies were completed on guppy fish, water fleas and freshwater algae which represented key species of marine life most likely to be impacted by the introduction of pesticide. Following application

    Read More
    Public
  • Osteopore continues winning streak with bone regeneration product approvals
    • News

    Osteopore continues winning streak with bone regeneration product approvals

    3D printing medtech company Osteopore (ASX: OSX) is set to continue their successful streak, following news that the company has received Australian Therapeutics Goods Administration (TGA) approval for three craniofacial products, after being placed into a trading halt Friday afternoon. The Osteomesh, Osteoplug, and Osteoplug-C, are used primarily to fill voids in a patient’s bone,

    Read More
    Public
  • TGA approves coronavirus testing kit, Genetic Signatures to flatten curve
    • News

    TGA approves coronavirus testing kit, Genetic Signatures to flatten curve

    Biotech company Genetic Signatures (ASX: GSS) is poised to play a major role in flattening the curve of coronavirus cases in Australia after the Therapeutics Goods Association (TGA) approved their SARS-CoV-2 Detection Kit for sale in Australia.  Regulatory approval in Australia follows authorisation which was granted in Europe 10 days ago with Genetic Signatures able

    Read More
    Public
  • «
  • ‹
  • 9
  • 10
  • 11
  • 12
  • ›

Login or register for free to access unlimited reading

Register Now!
  • News

  • Opinion

  • Satire

  • About

  • Contact Us

  • Subscribe

The content published on this website is solely for general information purposes and is not to be construed as financial advice. Should you seek financial advice you should consult with an appropriately qualified person. Opinions expressed on this site are subject to change without notice and The Sentiment who produced this content is under no obligation to keep the information current. The Sentiment, affiliated companies & associates may have a conflict of interest with companies discussed on the website due to commercial arrangements, for example they may be shareholders in the company, be engaged by them to assist in investor communications or receive commission/brokerage for funds raised.

Copyright © 2020 The Sentiment. All rights reserved.
Subscribe

Enter your email address below to subscribe to The Sentiment’s weekly newsletter, highlighting the top news, research, opinion and satire articles shaping ASX investor sentiment.

The Sentiment respects your privacy and will not spam you. View our privacy policy here.